Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Declan G Murphy

Showing results (401-410 of 415) with videos related to

Pageof 42
Sort By:
Nature Medicine|November 10, 2020
Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndromeRobert W Davies, Ania M Fiksinski, Elemi J Breetvelt, et al.
European Urology|July 28, 2018
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed TherapyMitchell G Lawrence, Daisuke Obinata, Shahneen Sandhu, et al.
Human Brain Mapping|January 15, 2024
Source-based morphometry reveals structural brain pattern abnormalities in 22q11.2 deletion syndromeRuiyang Ge, Christopher R K Ching, Anne S Bassett, et al.
European Urology|July 3, 2026
Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) DiagnosticsStefano Fanti, Fabio Turco, Bertrand Tombal, et al.
The American Journal of Psychiatry|February 13, 2020
Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric IllnessChristopher R K Ching, Boris A Gutman, Daqiang Sun, et al.
European Urology|February 1, 2020
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019Silke Gillessen, Gerhardt Attard, Tomasz M Beer, et al.
European Urology|April 20, 2022
Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al.
European Urology|April 8, 2022
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al.
European Urology|April 22, 2022
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021Silke Gillessen, Andrew Armstrong, Gert Attard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
Pageof 42

Showing results (401-410 of 415) with videos related to

Sort By:
Pageof 42
Nature Medicine|November 10, 2020
Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndromeRobert W Davies, Ania M Fiksinski, Elemi J Breetvelt, et al.
European Urology|July 28, 2018
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed TherapyMitchell G Lawrence, Daisuke Obinata, Shahneen Sandhu, et al.
Human Brain Mapping|January 15, 2024
Source-based morphometry reveals structural brain pattern abnormalities in 22q11.2 deletion syndromeRuiyang Ge, Christopher R K Ching, Anne S Bassett, et al.
European Urology|July 3, 2026
Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) DiagnosticsStefano Fanti, Fabio Turco, Bertrand Tombal, et al.
The American Journal of Psychiatry|February 13, 2020
Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric IllnessChristopher R K Ching, Boris A Gutman, Daqiang Sun, et al.
European Urology|February 1, 2020
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019Silke Gillessen, Gerhardt Attard, Tomasz M Beer, et al.
European Urology|April 20, 2022
Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al.
European Urology|April 8, 2022
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al.
European Urology|April 22, 2022
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021Silke Gillessen, Andrew Armstrong, Gert Attard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
Pageof 42